A carregar...
Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies
In 2014, the survival benefits seen in REGARD and RAINBOW studies led the way for the regulatory approval of ramucirumab in the second line setting in oesophagogastric (OG) cancer. Trials of other drugs targeting the vascular endothelial growth factor (VEGF) pathway have met with mixed results but t...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6647870/ https://ncbi.nlm.nih.gov/pubmed/31380271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00618 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|